Henan Cancer Hospital

Henan Cancer Hospital logo
πŸ‡¨πŸ‡³China
Ownership
Private
Established
1977-01-01
Employees
-
Market Cap
-
Website
http://www.anti-cancer.com.cn

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

First Posted Date
2022-03-25
Last Posted Date
2023-09-25
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
134
Registration Number
NCT05296577
Locations
πŸ‡¨πŸ‡³

Henan Cancer Hospital, Zhengzhou, Henan, China

Clinical Study on the Safety of Double and a Half Layered Esophagojejunal Anastomosis in Curative Gastrectomy

First Posted Date
2022-03-16
Last Posted Date
2022-03-16
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
21
Registration Number
NCT05282563
Locations
πŸ‡¨πŸ‡³

Henan cancer hopital, Zhengzhou, Henan, China

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

First Posted Date
2022-03-11
Last Posted Date
2022-09-16
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
40
Registration Number
NCT05276167
Locations
πŸ‡¨πŸ‡³

BR-PRG, Zhengzhou, Henan, China

An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC

First Posted Date
2022-02-23
Last Posted Date
2022-02-23
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
30
Registration Number
NCT05252091

Anti-emetic Prophylaxis With or Without Dexamethasone

First Posted Date
2022-02-16
Last Posted Date
2024-10-10
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
442
Registration Number
NCT05242874
Locations
πŸ‡¨πŸ‡³

Henan cancer hospital, Zhengzhou, Henan, China

πŸ‡¨πŸ‡³

Henan cacer hospital, Henan, Henan, China

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2022-01-26
Last Posted Date
2023-05-18
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
30
Registration Number
NCT05209620
Locations
πŸ‡¨πŸ‡³

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2022-01-26
Last Posted Date
2022-01-26
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
73
Registration Number
NCT05207735

Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.

First Posted Date
2022-01-12
Last Posted Date
2024-02-07
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
40
Registration Number
NCT05189483
Locations
πŸ‡¨πŸ‡³

Department of Bone and Soft Tissue, Henan Cancer Hospital, Zhengzhou, Henan, China

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2022-01-04
Last Posted Date
2022-08-19
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
42
Registration Number
NCT05177068
Locations
πŸ‡¨πŸ‡³

Henan Tumor Hospital, Zhengzhou, Henan, China

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

First Posted Date
2022-01-04
Last Posted Date
2024-12-17
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
46
Registration Number
NCT05176080
Locations
πŸ‡¨πŸ‡³

Henan Cancer Hospital, Zhengzhou, Henan, China

Β© Copyright 2024. All Rights Reserved by MedPath